Clinical trial
Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus…
NCT00197236 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00197236 |
|---|---|
| Title | Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months |
| Official title | Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 Months of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis A |
| Intervention type | Biological |
| Interventions | Havrix™, Infanrix™, ActHIB™ |
| Enrollment | 468 |
| Start date | Nov 11, 2003 |
| Primary completion | Dec 3, 2007 |
| Completion | Dec 3, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Aug 20, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: